Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  EGFR inhibitor AZD9291
Find trials that include:  Any drugs shown
Results 1-9 of 9 for your search:
Start Over
AZD9291 Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: D5160C00003, NCI-2014-02081, NCT02151981
AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D5160C00007, NCI-2015-00219, 2014-002694-11, U1111-1160-2242, NCT02296125
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EAY131, NCI-2015-00054, EAY131-A, EAY131-B, EAY131-E, EAY131-F, EAY131-G, EAY131-H, EAY131-Q, EAY131-R, EAY131-U, EAY131-V, NCT02465060
AZD9291 in Combination With Ascending Doses of Novel Therapeutics
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D5160C00006, NCI-2014-02005, NCT02143466
Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment
Phase: Phase I
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology
Age: 18 and over
Trial IDs: D5160C00008, NCI-2014-02545, 2014-001515-39, NCT02161770
EGFR Inhibitor AZD9291 and Necitumumab in Treating Patients with EGFR-Positive Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PhI-77, NCI-2015-01053, 9898, NCT02496663
TORC1/2 Inhibitor INK128 and EGFR Inhibitor AZD9291 in Treating Patients with Advanced EGFR Mutation Positive Non-small Cell Lung Cancer after Progression on a Previous EGFR Tyrosine Kinase Inhibitor
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PJC-020, NCI-2015-01139, 9910, 9910/PJC-020, NCT02503722
EGFR Inhibitor AZD9291 and Navitoclax in Treating Patients with EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9903, NCI-2015-01270, NCT02520778
AZD9291 US Expanded Access Program
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: D5160C00021, NCI-2015-01314, NCT02451852
Start Over